Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome

Frontiers in Pharmacology

Volumn 9, Issue , 2018, Pages

  Ðanić, Maja ^a   Stanimirov, Bojan ^a   Pavlović, Nebojša ^a   Goločorbin Kon, Svetlana ^a   Al Salami, Hani ^b   Stankov, Karmen ^a   Mikov, Momir ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; Bile acids; Diabetes; Farnesoid X receptor; Gut microbiota; Lipoprotein; Metabolic syndrome; Transmembrane G protein coupled receptor 5

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; LITHOCHOLIC ACID; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID;

ATHEROSCLEROSIS; CHOLELITHIASIS; CHOLESTASIS; DRUG EFFECT; DRUG SYNTHESIS; DRUG USE; ENERGY METABOLISM; ENTEROHEPATIC CIRCULATION; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SIGNAL TRANSDUCTION; ZELLWEGER SYNDROME;

EID: 85068403748     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2018.01382     Document Type: Review

References (182)

1. Adorini, L., Pruzanski, M., and Shapiro, D. (2012). Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 17, 988-997. doi: 10.1016/j.drudis.2012.05.012
2. Aguilar, M., Bhuket, T., Torres, S., Liu, B., and Wong, R. J. (2015). Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313, 1973-1974. doi: 10.1001/jama.2015.4260
3. Ajouz, H., Mukherji, D., and Shamseddine, A. (2014). Secondary bile acids: an underrecognized cause of colon cancer. World J. Surg. Oncol. 12, 164-164. doi: 10.1186/1477-7819-12-164
4. Alpert, M. A., Karthikeyan, K., Abdullah, O., and Ghadban, R. (2018). Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog. Cardiovasc. Dis. 61, 114-123. doi: 10.1016/j.pcad.2018.07.012
5. Al-Salami, H., Butt, G., Tucker, I., Golocorbin-Kon, S., and Mikov, M. (2012). Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur. J. Drug Metab. Pharmacokinet. 37, 99-108. doi: 10.1007/s13318-011-0060-y
6. Al-Salami, H., Butt, G., Tucker, I., and Mikov, M. (2008). Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find. Exp. Clin. Pharmacol. 30, 107-113. doi: 10.1358/mf.2008.30.2.1159652
7. Amaral, J. D., Xavier, J. M., Steer, C. J., and Rodrigues, C. M. (2010). The role of p53 in apoptosis. Discov. Med. 9, 145-152.
8. Ashby, K., Navarro Almario, E. E., Tong, W., Borlak, J., Mehta, R., and Chen, M. (2018). Review article: therapeutic bile acids and the risks for hepatotoxicity. Aliment. Pharmacol. Ther. 47, 1623-1638. doi: 10.1111/apt.14678
9. Baghdasaryan, A., Chiba, P., and Trauner, M. (2014). Clinical application of transcriptional activators of bile salt transporters. Mol. Aspects Med. 37, 57-76. doi: 10.1016/j.mam.2013.12.001
10. Bellanti, F., Villani, R., Tamborra, R., Blonda, M., Iannelli, G., di Bello, G., et al. (2018). Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression. Redox Biol. 15, 86-96. doi: 10.1016/j.redox.2017.11.016
11. Benedict, M., and Zhang, X. (2017). Non-alcoholic fatty liver disease: an expanded review. World J. Hepatol. 9, 715-732. doi: 10.4254/wjh.v9.i16.715
12. Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., et al. (2012). Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J. Clin. Invest. 122, 4667-4674. doi: 10.1172/jci64895
13. Brufau, G., Stellaard, F., Prado, K., Bloks, V. W., Jonkers, E., Boverhof, R., et al. (2010). Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52, 1455-1464. doi: 10.1002/hep.23831
14. Buchman, C. D., Chai, S. C., and Chen, T. (2018). A current structural perspective on PXR and CAR in drug metabolism. Expert Opin. Drug Metab. Toxicol. 14, 635-647. doi: 10.1080/17425255.2018.1476488
15. Carazo, A., Hyrsova, L., Dusek, J., Chodounska, H., Horvatova, A., Berka, K., et al. (2017). Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol. Lett. 265, 86-96. doi: 10.1016/j.toxlet. 2016.11.013
16. Cariou, B., Duran-Sandoval, D., Kuipers, F., and Staels, B. (2005). Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 146, 981-983. doi: 10.1210/en.2004-1595
17. Chávez-Talavera, O., Tailleux, A., Lefebvre, P., and Staels, B. (2017). Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055
18. Chen, G., Yang, L., Zhang, H., Tucker, I. G., and Fawcett, J. P. (2012). Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers. Int. J. Pharm. 433, 89-93. doi: 10.1016/j.ijpharm.2012.04.077
19. Chennamsetty, I., Claudel, T., Kostner, K. M., Trauner, M., and Kostner, G. M. (2012). FGF19 signaling cascade suppresses APOA gene expression. Arterioscler. Thromb. Vasc. Biol. 32, 1220-1227. doi: 10.1161/atvbaha.111. 243055
20. Chiang, J. Y. (2009). Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966.
21. Chiang, J. Y. (2013). Bile acid metabolism and signaling. Compr. Physiol. 3, 1191-1212. doi: 10.1002/cphy.c120023
22. Chiang, J. Y. (2015). Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases. Hepatology 62, 1315-1317. doi: 10.1002/hep. 27964
23. Chun, H. S., and Low, W. C. (2012). Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology 292, 105-112. doi: 10.1016/j. tox.2011.11.020
24. Chung, J., An, S. H., Kang, S. W., and Kwon, K. (2016). Ursodeoxycholic acid (UDCA) exerts anti-atherogenic effects by inhibiting RAGE signaling in diabetic atherosclerosis. PLoS One 11:e0147839. doi: 10.1371/journal.pone. 0147839
25. Chung, J., Kim, K. H., Lee, S. C., An, S. H., and Kwon, K. (2015). Ursodeoxycholic acid (UDCA) exerts anti-atherogenic effects by inhibiting endoplasmic reticulum (ER) stress induced by disturbed flow. Mol. Cells 38, 851-858. doi: 10.14348/molcells.2015.0094
26. Cipriani, S., Mencarelli, A., Palladino, G., and Fiorucci, S. (2010). FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771-784. doi: 10.1194/ jlr.M001602
27. Comeglio, P., Morelli, A., Adorini, L., Maggi, M., and Vignozzi, L. (2017). Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert Opin. Investig. Drugs 26, 1215-1228. doi: 10.1080/13543784.2017.138 5760
28. Cybulsky, A. V. (2017). Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases. Nat. Rev. Nephrol. 13, 681-696. doi: 10.1038/nrneph.2017.129
29. Danic, M., Pavlovic, N., Stanimirov, B., Vukmirovic, S., Nikolic, K., Agbaba, D., et al. (2016). The influence of bile salts on the distribution of simvastatin in the octanol/buffer system. Drug Dev. Ind. Pharm. 42, 661-667. doi: 10.3109/ 03639045.2015.1067626
30. Dawson, P. A., Lan, T., and Rao, A. (2009). Bile acid transporters. J. Lipid Res. 50, 2340-2357. doi: 10.1194/jlr.R900012-JLR200
31. de Boer, J. F., Schonewille, M., Boesjes, M., Wolters, H., Bloks, V. W., Bos, T., et al. (2017). Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology 152, 1126-1138.e6. doi: 10.1053/j.gastro. 2016.12.037
32. de Boer, J. F., Bloks, V. W., Heiner-Fokkema, M. R., and Kuipers, F. (2018). New insights in the multiple roles of bile acids and their signaling pathways in metabolic control. Curr. Opin. Lipidol. 29, 194-202. doi: 10.1097/MOL. 0000000000000508
33. De Giorgi, S., Campos, V., Egli, L., Toepel, U., Carrel, G., Cariou, B., et al. (2015). Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: a cross-sectional pilot study. Clin. Nutr. 34, 911-917. doi: 10.1016/j.clnu.2014.09.018
34. DeGruttola, A. K., Low, D., Mizoguchi, A., and Mizoguchi, E. (2016). Current understanding of dysbiosis in disease in human and animal models. Inflamm. Bowel Dis. 22, 1137-1150. doi: 10.1097/MIB.0000000000000750
35. Demir, M., Lang, S., and Steffen, H. M. (2015). Nonalcoholic fatty liver disease - current status and future directions. J. Dig. Dis. 16, 541-557. doi: 10.1111/1751-2980.12291
36. Deutschmann, K., Reich, M., Klindt, C., Droge, C., Spomer, L., Haussinger, D., et al. (2018). Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim. Biophys. Acta 1864, 1319-1325. doi: 10.1016/j.bbadis.2017.08.021
37. Duboc, H., Tache, Y., and Hofmann, A. F. (2014). The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig. Liver Dis. 46, 302-312. doi: 10.1016/j.dld.2013.10.021
38. Dutia, R., Embrey, M., O'Brien, S., Haeusler, R. A., Agenor, K. K., Homel, P., et al. (2016). Temporal changes in bile acid levels and 12alpha-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int. J. Obes. 40:554. doi: 10.1038/ijo.2015.250
39. Everard, A., and Cani, P. D. (2014). Gut microbiota and GLP-1. Rev. Endocr. Metab. Disord. 15, 189-196. doi: 10.1007/s11154-014-9288-6
40. Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., et al. (2015). Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159-165. doi: 10.1038/nm.3760
41. Feneberg, A., and Malfertheiner, P. (2012). Epidemic trends of obesity with impact on metabolism and digestive diseases. Dig. Dis. 30, 143-147. doi: 10.1159/ 000336660
42. Ferrebee, C. B., and Dawson, P. A. (2015). Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm. Sin. B 5, 129-134. doi: 10.1016/j.apsb.2015.01.001
43. Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H. U., Altorjay, I., Farkkila, M., et al. (2017). NorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J. Hepatol. 67, 549-558. doi: 10.1016/j.jhep.2017.05.009
44. Fickert, P., Wagner, M., Marschall, H. U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., et al. (2006). 24-NorUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465-481. doi: 10.1053/j.gastro.2005. 10.018
45. Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., et al. (2004). The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512.
46. Fiorucci, S., Cipriani, S., Baldelli, F., and Mencarelli, A. (2010). Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 49, 171-185. doi: 10.1016/j.plipres.2009.11.001
47. Fiorucci, S., Clerici, C., Antonelli, E., Orlandi, S., Goodwin, B., Sadeghpour, B. M., et al. (2005). Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313, 604-612. doi: 10.1124/jpet.104.079665
48. Fiorucci, S., Mencarelli, A., Palladino, G., and Cipriani, S. (2009). Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30, 570-580. doi: 10.1016/j.tips.2009. 08.001
49. Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E., and Santucci, L. (2007). Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13, 298-309. doi: 10.1016/j.molmed.2007.06.001
50. Fu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M., et al. (2004). Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594-2603. doi: 10.1210/en.2003-1671
51. Gabbia, D., Pozza, A. D., Albertoni, L., Lazzari, R., Zigiotto, G., Carrara, M., et al. (2017). Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World J. Gastroenterol. 23, 7519-7530. doi: 10.3748/wjg.v23.i42. 7519
52. Gardmo, C., Tamburro, A., Modica, S., and Moschetta, A. (2011). Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim. Biophys. Acta 1812, 836-841. doi: 10.1016/j.bbadis.2011.03.009
53. Garvey, W. T., Maianu, L., Hancock, J. A., Golichowski, A. M., and Baron, A. (1992). Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes Metab. Res. Rev. 41, 465-475.
54. Garvey, W. T., Maianu, L., Huecksteadt, T. P., Birnbaum, M. J., Molina, J. M., and Ciaraldi, T. P. (1991). Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J. Clin. Invest. 87, 1072-1081. doi: 10.1172/jci115068
55. Gautier, T., de Haan, W., Grober, J., Ye, D., Bahr, M. J., Claudel, T., et al. (2013). Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J. Lipid Res. 54, 2195-2205. doi: 10.1194/jlr.M038141
56. Gerken, G., and Nitschmann, S. (2017). [Obeticholic acid in primary biliary cholangitis: PBC OCA international study of efficacy (POISE)]. Internist 58, 202-204. doi: 10.1007/s00108-016-0185-9
57. Gioiello, A., Cerra, B., Mostarda, S., Guercini, C., Pellicciari, R., and Macchiarulo, A. (2014). Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. Curr. Top. Med. Chem. 14, 2159-2174.
58. Goto, T., Itoh, M., Suganami, T., Kanai, S., Shirakawa, I., Sakai, T., et al. (2018). Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci. Rep. 8:8157. doi: 10.1038/s41598-018-26383-8
59. Gruben, N., Shiri-Sverdlov, R., Koonen, D. P., and Hofker, M. H. (2014). Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison? Biochim. Biophys. Acta 1842, 2329-2343. doi: 10.1016/j. bbadis.2014.08.004
60. Guo, C., Chen, W. D., and Wang, Y. D. (2016). TGR5, not only a metabolic regulator. Front. Physiol. 7:646. doi: 10.3389/fphys.2016.00646
61. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., and Ferrannini, E. (2013). Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes Metab. Res. Rev. 62, 4184-4191. doi: 10.2337/ db13-0639
62. Halilbasic, E., Fuchs, C., Hofer, H., Paumgartner, G., and Trauner, M. (2015). Therapy of primary sclerosing cholangitis-today and tomorrow. Dig. Dis. 33(Suppl. 2), 149-163. doi: 10.1159/000440827
63. Han, J.-L., and Lin, H.-L. (2014). Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. World J. Gastroenterol. 20, 17737-17745. doi: 10.3748/wjg.v20.i47.17737
64. Hanson, R. L., Imperatore, G., Bennett, P. H., and Knowler, W. C. (2002). Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes Metab. Res. Rev. 51, 3120-3127.
65. He, F., Li, J., Mu, Y., Kuruba, R., Ma, Z., Wilson, A., et al. (2006). Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98, 192-199. doi: 10.1161/01.res.0000200400.55 539.85
66. Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., et al. (2015). Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751-761.e8. doi: 10.1053/j.gastro.2014.12.005
67. Hofmann, A. F. (2004). Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36, 703-722. doi: 10.1081/ dmr-200033475
68. Hofmann, A. F., and Hagey, L. R. (2008). Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65, 2461-2483. doi: 10.1007/s00018-008-7568-6
69. Hou, Y., Yang, H., Cui, Z., Tai, X., Chu, Y., and Guo, X. (2017). Tauroursodeoxycholic acid attenuates endoplasmic reticulum stress and protects the liver from chronic intermittent hypoxia induced injury. Exp. Ther. Med. 14, 2461-2468. doi: 10.3892/etm.2017.4804
70. Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., and Dent, P. (2009). Bile acids as regulatory molecules. J. Lipid Res. 50, 1509-1520. doi: 10.1194/jlr. R900007-JLR200
71. Inagaki, T., Moschetta, A., Lee, Y. K., Peng, L., Zhao, G., Downes, M., et al. (2006). Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 3920-3925. doi: 10.1073/pnas. 0509592103
72. Jansen, P. L., van Werven, J., Aarts, E., Berends, F., Janssen, I., Stoker, J., et al. (2011). Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 29, 48-51. doi: 10.1159/000324128
73. Jia, W., Xie, G., and Jia, W. (2017). Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111-128. doi: 10.1038/nrgastro.2017.119
74. Jiao, Y., Lu, Y., and Li, X. Y. (2015). Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol. Sin. 36, 44-50. doi: 10.1038/aps.2014.116
75. Kang, Y. M., and Jung, C. H. (2016). Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol. Metab. 31, 258-274. doi: 10.3803/EnM. 2016.31.2.258
76. Katona, B. W., Cummins, C. L., Ferguson, A. D., Li, T., Schmidt, D. R., Mangelsdorf, D. J., et al. (2007). Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids. J. Med. Chem. 50, 6048-6058. doi: 10.1021/jm0707931
77. Katsuma, S., Hirasawa, A., and Tsujimoto, G. (2005). Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386-390.
78. Kaur, J. (2014). A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014:943162. doi: 10.1155/2014/943162
79. Kemper, J. K. (2011). Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 1812, 842-850. doi: 10.1016/j.bbadis.2010.11.011
80. Kida, T., Tsubosaka, Y., Hori, M., Ozaki, H., and Murata, T. (2013). Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33, 1663-1669. doi: 10.1161/atvbaha.113.301565
81. Kitade, H., Chen, G., Ni, Y., and Ota, T. (2017). Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients 9:E387. doi: 10.3390/nu9040387
82. Knip, M., and Siljander, H. (2016). The role of the intestinal microbiota in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 12, 154-167. doi: 10.1038/nrendo. 2015.218
83. Kuhajda, I., Poša, M., Jakovljeviæ, V., Ivetiæ, V., and Mikov, M. (2009). Effect of 12-monoketocholic acid on modulation of analgesic action of morphine and tramadol. Eur. J. Drug Metab. Pharmacokinet. 34, 73-78.
84. Kumar, D. P., Asgharpour, A., Mirshahi, F., Park, S. H., Liu, S., Imai, Y., et al. (2016). Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis. J. Biol. Chem. 291, 6626-6640. doi: 10.1074/jbc.M115.699504
85. Kumar, D. P., Rajagopal, S., Mahavadi, S., Mirshahi, F., Grider, J. R., Murthy, K. S., et al. (2012). Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem. Biophys. Res. Commun. 427, 600-605. doi: 10.1016/j.bbrc.2012.09.104
86. Kuno, T., Hirayama-Kurogi, M., Ito, S., and Ohtsuki, S. (2018). Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci. Rep. 8:1253. doi: 10.1038/s41598-018-19545-1
87. Lam, D. W., and LeRoith, D. (2012). The worldwide diabetes epidemic. Curr. Opin. Endocrinol. Diabetes Obes. 19, 93-96. doi: 10.1097/MED.0b013e328350583a
88. Lambert, G., Amar, M. J., Guo, G., Brewer, H. B. Jr., Gonzalez, F. J., and Sinal, C. J. (2003). The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563-2570. doi: 10.1074/jbc.M209525200
89. Li, J., Wilson, A., Kuruba, R., Zhang, Q., Gao, X., He, F., et al. (2008). FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 77, 169-177. doi: 10.1093/cvr/cvm016
90. Li, S., Tan, H. Y., Wang, N., Hong, M., Li, L., Cheung, F., et al. (2016). Substitutes for bear bile for the treatment of liver diseases: research progress and future perspective. Evid. Based Complement. Alternat. Med. 2016:4305074. doi: 10. 1155/2016/4305074
91. Li, T., and Chiang, J. Y. (2013). Nuclear receptors in bile acid metabolism. Drug Metab. Rev. 45, 145-155. doi: 10.3109/03602532.2012.740048
92. Li, T., and Chiang, J. Y. L. (2015). Bile acids as metabolic regulators. Curr. Opin. Gastroenterol. 31, 159-165. doi: 10.1097/MOG.0000000000000156
93. Li, T., Francl, J. M., Boehme, S., and Chiang, J. Y. (2013). Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology 58, 1111-1121. doi: 10.1002/hep.26427
94. Li, Y. T., Swales, K. E., Thomas, G. J., Warner, T. D., and Bishop-Bailey, D. (2007). Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27, 2606-2611. doi: 10.1161/ atvbaha.107.152694
95. Lobysheva, E., Taylor, C. M., Marshall, G. R., and Kisselev, O. G. (2018). Tauroursodeoxycholic acid binds to the G-protein site on light activated rhodopsin. Exp. Eye Res. 170, 51-57. doi: 10.1016/j.exer.2018.02.015
96. Madsbad, S., Dirksen, C., and Holst, J. J. (2014). Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2, 152-164. doi: 10.1016/s2213-8587(13)70218-3
97. Madsbad, S., and Holst, J. J. (2014). GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes Metab. Res. Rev. 63, 3172-3174. doi: 10.2337/db14-0935
98. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., et al. (2002). Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719.
99. Maruyama, T., Tanaka, K., Suzuki, J., Miyoshi, H., Harada, N., Nakamura, T., et al. (2006). Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J. Endocrinol. 191, 197-205. doi: 10.1677/joe.1. 06546
100. Massafra, V., and van Mil, S. W. C. (2018). Farnesoid X receptor: a “homeostat” for hepatic nutrient metabolism. Biochim. Biophys. Acta 1864, 45-59. doi: 10.1016/ j.bbadis.2017.10.003
101. McCracken, E., Monaghan, M., and Sreenivasan, S. (2018). Pathophysiology of the metabolic syndrome. Clin. Dermatol. 36, 14-20. doi: 10.1016/j.clindermatol. 2017.09.004
102. Mencarelli, A., and Fiorucci, S. (2010). FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. 14, 79-92. doi: 10.1111/j.1582-4934.2009.00997.x
103. Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., and Cordova-Gallardo, J. (2018). New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int. J. Mol. Sci. 19:E2034. doi: 10. 3390/ijms19072034
104. Mertens, K. L., Kalsbeek, A., Soeters, M. R., and Eggink, H. M. (2017). Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front. Neurosci. 11:617. doi: 10.3389/fnins.2017.00617
105. Miao, L., Dong, Y., Zhou, F. B., Chang, Y. L., Suo, Z. G., and Ding, H. Q. (2018). Protective effect of tauroursodeoxycholic acid on the autophagy of nerve cells in rats with acute spinal cord injury. Eur. Rev. Med. Pharmacol. Sci. 22, 1133-1141. doi: 10.26355/eurrev_201802_14402
106. Mikov, M., Ðanić, M., Pavlović, N., Stanimirov, B., Goloèorbin-Kon, S., Stankov, K., et al. (2017). Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics. Eur. J. Drug Metab. Pharmacokinet. 43, 269-280. doi: 10.1007/s13318-017-0441-y
107. Mikov, M., and Fawcett, J. P. (2006). Chemistry, biosynthesis, analysis, chemical & metabolic transformations and pharmacology. Eur. J. Drug Metab. Pharmacokinet. 31, 133-134.
108. Mikov, M., Fawcett, J. P., Kuhajda, K., and Kevresan, S. (2006). Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur. J. Drug Metab. Pharmacokinet. 31, 237-251.
109. Mircioiu, I., Anuta, V., Ibrahim, N., and Mircioiu, C. (2012). Dissolution of tamoxifen in biorelevant media. A two phase release model. Farmacia 6, 315-324.
110. Miyazaki-Anzai, S., Masuda, M., Levi, M., Keenan, A. L., and Miyazaki, M. (2014). Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One 9:e108270. doi: 10.1371/journal.pone.0108270
111. Molinaro, A., Wahlstrom, A., and Marschall, H. U. (2018). Role of bile acids in metabolic control. Trends Endocrinol. Metab. 29, 31-41. doi: 10.1016/j.tem. 2017.11.002
112. Monte, M. J., Marin, J. J. G., Antelo, A., and Vazquez-Tato, J. (2009). Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804-816. doi: 10.3748/wjg.15.804
113. Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H. U., Kipnes, M., et al. (2013). Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e1. doi: 10.1053/j.gastro.2013. 05.042
114. Mueller, M., and Castro, R. E. (2018). Ursodeoxycholic acid: effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver Int. 38, 523-531. doi: 10.1111/liv.13562
115. Mullard, A. (2016). 2015 FDA drug approvals. Nat. Rev. Drug Discov. 15, 73-76. doi: 10.1038/nrd.2016.15
116. Nakahara, M., Fujii, H., Maloney, P. R., Shimizu, M., and Sato, R. (2002). Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J. Biol. Chem. 277, 37229-37234. doi: 10.1074/jbc.M206749200
117. Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., et al. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965. doi: 10.1016/s0140-6736(14)61933-4
118. Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., et al. (2016). A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631-643. doi: 10.1056/NEJMoa1509840
119. Osto, M., Abegg, K., Bueter, M., le Roux, C. W., Cani, P. D., and Lutz, T. A. (2013). Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiol. Behav. 119, 92-96. doi: 10.1016/j.physbeh.2013. 06.008
120. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., et al. (2006). Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140. doi: 10.1126/ science.1128294
121. Pan, X., Zhang, Y., Wang, L., and Hussain, M. M. (2010). Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP. Cell Metab. 12, 174-186. doi: 10.1016/j.cmet.2010.05.014
122. Papazyan, R., Liu, X., Liu, J., Dong, B., Plummer, E. M., Lewis, R. D. II, et al. (2018). FXR activation by obeticholic acid or non-steroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J. Lipid Res. 59, 982-993. doi: 10.1194/jlr.M081935
123. Paumgartner, G., and Beuers, U. (2002). Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525-531. doi: 10.1053/jhep.2002.36088
124. Pavek, P. (2016). Pregnane X receptor (PXR)-mediated gene repression and crosstalk of PXR with other nuclear receptors via coactivator interactions. Front. Pharmacol. 7:456. doi: 10.3389/fphar.2016.00456
125. Pavlovic, N., Stanimirov, B., and Mikov, M. (2017). Bile acids as novel pharmacological agents: the interplay between gene polymorphisms, epigenetic factors and drug response. Curr. Pharm. Des. 23, 187-215. doi: 10.2174/ 1381612822666161006161409
126. Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., et al. (2002). 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572.
127. Pellicciari, R., Gioiello, A., Macchiarulo, A., Thomas, C., Rosatelli, E., Natalini, B., et al. (2009). Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961. doi: 10.1021/jm901390p
128. Pencek, R., Marmon, T., Roth, J. D., Liberman, A., Hooshmand-Rad, R., and Young, M. A. (2016). Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes. Metab. 18, 936-940. doi: 10.1111/dom.12681
129. Penney, N. C., Kinross, J., Newton, R. C., and Purkayastha, S. (2015). The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int. J. Obes. 39, 1565-1574. doi: 10.1038/ijo. 2015.115
130. Perez, M. J., and Briz, O. (2009). Bile-acid-induced cell injury and protection. World J. Gastroenterol. 15, 1677-1689. doi: 10.3748/wjg.15.1677
131. Pols, T. W., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M. H., Thomas, C., et al. (2011). TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14, 747-757. doi: 10.1016/j.cmet. 2011.11.006
132. Pournaras, D. J., Glicksman, C., Vincent, R. P., Kuganolipava, S., Alaghband-Zadeh, J., Mahon, D., et al. (2012). The role of bile after roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153, 3613-3619. doi: 10.1210/en.2011-2145
133. Prinz, P., Hofmann, T., Ahnis, A., Elbelt, U., Goebel-Stengel, M., Klapp, B. F., et al. (2015). Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front. Neurosci. 9:199. doi: 10.3389/fnins.2015.00199
134. Qin, P., Tang, X., Elloso, M. M., and Harnish, D. C. (2006). Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am. J. Physiol. Heart Circ. Physiol. 291, H741-H747. doi: 10.1152/ajpheart.01182.2005
135. Quercia, I., Dutia, R., Kotler, D. P., Belsley, S., and Laferrere, B. (2014). Gastrointestinal changes after bariatric surgery. Diabetes Metab. 40, 87-94. doi: 10.1016/j.diabet.2013.11.003
136. Raghow, R. (2015). Menage-a-trois of bariatric surgery, bile acids and the gut microbiome. World J. Diabetes 6, 367-370. doi: 10.4239/wjd.v6.i3.367
137. Ramirez-Perez, O., Cruz-Ramon, V., Chinchilla-Lopez, P., and Mendez-Sanchez, N. (2017). The role of the gut microbiota in bile acid metabolism. Ann. Hepatol. 16, s15-s20. doi: 10.5604/01.3001.0010.5494
138. Renga, B., Mencarelli, A., Migliorati, M., Distrutti, E., and Fiorucci, S. (2009). Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J. Gastroenterol. 15, 2097-2108.
139. Renga, B., Mencarelli, A., Vavassori, P., Brancaleone, V., and Fiorucci, S. (2010). The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 1802, 363-372. doi: 10.1016/j.bbadis.2010.01.002
140. Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D. J., and Hylemon, P. B. (2016). Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7, 22-39. doi: 10.1080/19490976.2015.1127483
141. Roda, A., Grigolo, B., Pellicciari, R., and Natalini, B. (1989). Structure-activity relationship studies on natural and synthetic bile acid analogs. Dig. Dis. Sci. 34, 24s-35s.
142. Roda, A., Hofmann, A. F., and Mysels, K. J. (1983). The influence of bile salt structure on self-association in aqueous solutions. J. Biol. Chem. 258, 6362-6370.
143. Rodrigues, P. M., Afonso, M. B., Simão, A. L., Carvalho, C. C., Trindade, A., Duarte, A., et al. (2017). miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis. 8:e2748. doi: 10.1038/cddis. 2017.172
144. Rosa, A. I., Duarte-Silva, S., Silva-Fernandes, A., Nunes, M. J., Carvalho, A. N., Rodrigues, E., et al. (2018). Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease. Mol. Neurobiol. 55, 9139-9155. doi: 10.1007/s12035-018-1062-4
145. Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., et al. (2014). FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183-188. doi: 10.1038/nature13135
146. Salehi, M., Prigeon, R. L., and D'Alessio, D. A. (2011). Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes Metab. Res. Rev. 60, 2308-2314. doi: 10.2337/db11-0203
147. Sanyal, A. J. (2011). NASH: a global health problem. Hepatol. Res. 41, 670-674. doi: 10.1111/j.1872-034X.2011.00824.x
148. Sato, H., Macchiarulo, A., Thomas, C., Gioiello, A., Une, M., Hofmann, A. F., et al. (2008). Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831-1841. doi: 10.1021/jm7015864
149. Schaap, F. G. (2012). Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr. Opin. Clin. Nutr. Metab. Care 15, 386-391. doi: 10.1097/ MCO.0b013e3283547171
150. Schoenfield, L. J., and Lachin, J. M. (1981). Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern. Med. 95, 257-282.
151. Shapiro, H., Kolodziejczyk, A. A., Halstuch, D., and Elinav, E. (2018). Bile acids in glucose metabolism in health and disease. J. Exp. Med. 215, 383-396. doi: 10.1084/jem.20171965
152. Shen, H., Zhang, Y., Ding, H., Wang, X., Chen, L., Jiang, H., et al. (2008). Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell. Physiol. Biochem. 22, 1-14. doi: 10.1159/000149779
153. Shimizu, H., Hagio, M., Iwaya, H., Tsuneki, I., Lee, J. Y., Fukiya, S., et al. (2014). Deoxycholic acid is involved in the proliferation and migration of vascular smooth muscle cells. J. Nutr. Sci. Vitaminol. 60, 450-454. doi: 10.3177/jnsv. 60.450
154. Sinisalo, J., Vanhanen, H., Pajunen, P., Vapaatalo, H., and Nieminen, M. S. (1999). Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br. J. Clin. Pharmacol. 47, 661-665. doi: 10.1046/j.1365-2125.1999. 00940.x
155. Stanimirov, B., Stankov, K., and Mikov, M. (2012). Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol. Belg. 75, 389-398.
156. Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J., Cook, T., Christe, M. E., et al. (2005). Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146, 984-991. doi: 10.1210/en.2004-0965
157. Stedman, C., Robertson, G., Coulter, S., and Liddle, C. (2004). Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279, 11336-11343. doi: 10.1074/jbc.M31025 8200
158. Stedman, C. A., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G., Moore, D. D., et al. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102, 2063-2068. doi: 10.1073/pnas.0409794102
159. Steiner, C., Othman, A., Saely, C. H., Rein, P., Drexel, H., von Eckardstein, A., et al. (2011). Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 6:e25006. doi: 10.1371/journal.pone.0025006
160. Stojančević, M., Bojic, G., Salami, H. A., and Mikov, M. (2014). The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr. Issues Mol. Biol. 16, 55-68.
161. Stojančević, M., Pavlović, N., Goločorbin-Kon, S., and Mikov, M. (2013). Application of bile acids in drug formulation and delivery. Front. Life Sci. 7, 112-122. doi: 10.1080/21553769.2013.879925
162. Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., et al. (2016). Role of bile acids in the regulation of the metabolic pathways. World J. Diabetes 7, 260-270. doi: 10.4239/wjd.v7.i13.260
163. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177. doi: 10.1016/j.cmet.2009.08.001
164. Trauner, M., Halilbasic, E., Claudel, T., Steinacher, D., Fuchs, C., Moustafa, T., et al. (2015). Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig. Dis. 33, 433-439. doi: 10.1159/000371904
165. Uppal, H., Toma, D., Saini, S. P., Ren, S., Jones, T. J., and Xie, W. (2005). Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41, 168-176. doi: 10.1002/hep.20512
166. Urizar, N. L., Dowhan, D. H., and Moore, D. D. (2000). The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 275, 39313-39317. doi: 10.1074/jbc.M007998200
167. van Nierop, F. S., Scheltema, M. J., Eggink, H. M., Pols, T. W., Sonne, D. P., Knop, F. K., et al. (2017). Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol. 5, 224-233. doi: 10.1016/s2213-8587(16)30155-3
168. Vaz, F. M., and Ferdinandusse, S. (2017). Bile acid analysis in human disorders of bile acid biosynthesis. Mol. Aspects Med. 56, 10-24. doi: 10.1016/j.mam.2017. 03.003
169. Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., et al. (2014). Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298. doi: 10. 1002/hep.26939
170. Vrieze, A., Out, C., Fuentes, S., Jonker, L., Reuling, I., Kootte, R. S., et al. (2014). Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60, 824-831. doi: 10.1016/j.jhep.2013.11.034
171. Wahlstrom, A., Sayin, S. I., Marschall, H. U., and Backhed, F. (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41-50. doi: 10.1016/j.cmet.2016.05.005
172. Walsh, L. K., Restaino, R. M., Neuringer, M., Manrique, C., and Padilla, J. (2016). Administration of tauroursodeoxycholic acid prevents endothelial dysfunction caused by an oral glucose load. Clin. Sci. 130, 1881-1888. doi: 10.1042/ cs20160501
173. Walters, J. R., Johnston, I. M., Nolan, J. D., Vassie, C., Pruzanski, M. E., and Shapiro, D. A. (2015). The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment. Pharmacol. Ther. 41, 54-64. doi: 10.1111/apt.12999
174. Wang, W., Zhao, J., Gui, W., Sun, D., Dai, H., Xiao, L., et al. (2018). Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br. J. Pharmacol. 175, 469-484. doi: 10.1111/bph.14095
175. Wang, Y. G., Zhou, J. M., Ma, Z. C., Li, H., Liang, Q. D., Tan, H. L., et al. (2012). Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: a possible mechanism for its hepatoprotective property against lithocholic acid-induced injury. Chem. Biol. Interact. 200, 11-20. doi: 10.1016/j. cbi.2012.08.023
176. Watanabe, M., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., et al. (2004). Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418. doi: 10. 1172/JCI200421025
177. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., and Feldstein, A. E. (2013). From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627-636. doi: 10.1038/nrgastro.2013.149
178. Yadav, H., Lee, J. H., Lloyd, J., Walter, P., and Rane, S. G. (2013). Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288, 25088-25097. doi: 10.1074/jbc.M113.452516
179. Yamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., et al. (2004). Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279, 23158-23165. doi: 10.1074/jbc.M31432 2200
180. Yang, L., Zhang, H., Fawcett, J. P., Mikov, M., and Tucker, I. G. (2011). Effect of bile salts on the transport of morphine-6-glucuronide in rat brain endothelial cells. J. Pharm. Sci. 100, 1516-1524. doi: 10.1002/jps.22390
181. Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., et al. (2006). Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 103, 1006-1011. doi: 10.1073/pnas.0506982103
182. Zwicker, B. L., and Agellon, L. B. (2013). Transport and biological activities of bile acids. Int. J. Biochem. Cell Biol. 45, 1389-1398. doi: 10.1016/j.biocel.2013.04.012